Ionis Pharmaceuticals (IONS) announced positive results from a phase II study on its investigational drug ION224 in adult patients with metabolic dysfunction-associated steatohepatitis (MASH) over 51 weeks.Study participants who received 90mg and 120mg doses of ION224 achieved the primary endpoint of statistically significant liver histologic improvement. This was measured by at least a two-point reduction in the non-alcoholic fatty liver disease (NAFLD) activity score, or NAS. A subgroup analysis indicated ...